At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|November 29, 2022
Dr. Webster on what the future holds for urology
Author(s)Urology Times staff
“It certainly seems that we're moving into medical management of advanced diseases,” says J. Christopher Webster, MD, FACS.
Advertisement
In this video, J. Christopher Webster, MD, FACS, makes his predictions for future advancements in urology over the next several years. Webster is a urologist with Colorado Urology in Westminster. He was interviewed at the
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5